Biomarin Pharmaceutical (FRA:BM8) Other Net Income (Loss) : €0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Other Net Income (Loss)?

Biomarin Pharmaceutical's Other Net Income (Loss) for the three months ended in Mar. 2025 was €0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was €0 Mil.

Biomarin Pharmaceutical's quarterly Other Net Income (Loss) increased from Sep. 2024 (€0 Mil) to Dec. 2024 (€0 Mil) but then declined from Dec. 2024 (€0 Mil) to Mar. 2025 (€0 Mil).

Biomarin Pharmaceutical's annual Other Net Income (Loss) declined from Dec. 2022 (€0 Mil) to Dec. 2023 (€-0 Mil) and declined from Dec. 2023 (€-0 Mil) to Dec. 2024 (€-0 Mil).

Biomarin Pharmaceutical Other Net Income (Loss) Historical Data

The historical data trend for Biomarin Pharmaceutical's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Other Net Income (Loss) Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Biomarin Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Biomarin Pharmaceutical Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Biomarin Pharmaceutical Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

BMRN:USA BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines